CagriSema and the Amylin Question: What a Chattanooga Physician Wants You to Understand

I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. CagriSema is investigational — not yet approved, not something I can prescribe today — so this is education, not a sales pitch. But the science behind it explains something I see in nearly every patient who plateaus, and it directly shapes how I already practice here in Tennessee.

What Is Amylin, and Why Does CagriSema Combine It With Semaglutide?

Most people know GLP-1 — the gut hormone that semaglutide mimics to quiet appetite. Amylin is a different hormone, released alongside insulin, that signals fullness through a separate part of the brainstem. Cagrilintide is a long-acting amylin analogue. CagriSema pairs it with semaglutide in a single weekly injection, so two distinct satiety pathways are engaged at once.

Why does that matter? Because researchers recently mapped, across multiple species, that amylin and semaglutide act on genuinely separate neural circuits — meaning the combination is more than the sum of its parts (Ludwig MQ et al, Nature Metabolism, 2026). And in rodent studies, roughly a third of CagriSema’s weight loss came from preserved energy expenditure rather than appetite suppression alone (Jacobsen JM et al, Nature Metabolism, 2025). That second point is the one I want you to remember — I will come back to it.

The Trial Numbers — Read With Care

In the pivotal REDEFINE 1 trial (3,417 adults with obesity, 68 weeks), CagriSema produced an average weight reduction of 20.4% on the intention-to-treat analysis, and 22.7% among patients who stayed on treatment, versus 3.0% on placebo (Garvey WT et al, New England Journal of Medicine, 2025).

Those are strong numbers. They are also honest numbers, and the honesty cuts both ways. When REDEFINE 1 first reported, some observers were underwhelmed, because an informal expectation of 25%-plus had been floating around. The drug hit its target and lowered blood pressure meaningfully — but only about 57% of patients reached the top dose, because tolerability led many to ease off. In a later head-to-head readout, CagriSema did not clearly beat tirzepatide on weight (Novo Nordisk topline, February 2026; not yet peer-reviewed).

I tell you this because it is exactly the kind of nuance a questionnaire-based telehealth service will never explain. A bigger headline number does not automatically mean a better drug for you — tolerability, dosing discipline, and how your body responds matter just as much. Group averages from a trial are not a promise to any individual.

The Part That Already Changes How I Practice in Chattanooga

Remember the energy-expenditure finding — that part of amylin’s benefit comes from blunting the body’s tendency to slow its metabolism as it loses weight? That metabolic slowdown, called adaptive thermogenesis, is the single biggest reason people plateau and rebound. It is the enemy in long-term weight management, and it is why “eat less, move more” eventually stops working.

CagriSema is one pharmacological way to fight it. But you do not need an unapproved drug to address metabolic adaptation. We already do it at Summit, with tools available today.

This is the throughline of everything I do. The frontier drugs in development — CagriSema, the triple agonists, the next-generation amylin agents — are all, in one way or another, trying to solve the same problem: how do you lose fat without your body fighting to put it back? The answer is never the molecule alone. It is the molecule plus deliberate dosing, plus muscle preservation, plus a physician who actually plans for the day you come off the medication.

When CagriSema is approved and proven in the real world, I will weigh it for my Tennessee patients on its merits — efficacy, tolerability, and how it fits a given person’s case. Until then, no one should put their health on hold waiting for it. The biology that makes weight loss hard is treatable now.

The Bottom Line for Chattanooga

CagriSema and the amylin class represent a real advance, and the energy-expenditure insight behind them validates an approach we already take seriously. But it is not yet available, and a strong trial average is not a personal guarantee. If you have plateaued — or you are afraid of regaining what you lose — the path forward is a physician who treats metabolic adaptation as the clinical problem it is.

Apply in about five minutes at summitmetabolichealth.com/apply. I review every application myself and reach out personally — no algorithms, no sales calls.